Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | TP53 | P04637 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluquazone SCHEMBL28193448 | 0.93 | MAPT (0.57) | MAPTTP53LMNARXFP1 | |
| SCHEMBL11480424 | 0.92 | MAPT (0.57) | MAPTTP53LMNARXFP1 | |
| SCHEMBL11470963 | 0.92 | MAPT (0.57) | MAPTTP53LMNARXFP1 | |
| SCHEMBL11468011 | 0.91 | MAPT (0.56) | MAPTTP53LMNARXFP1 | |
| SCHEMBL11479018 | 0.90 | RXFP1 (0.51) | MAPTTP53LMNARXFP1KCNH2 | |
| SCHEMBL11472800 | 0.89 | MAPT (0.59) | MAPTTP53LMNARXFP1 | |
| SCHEMBL11470918 | 0.89 | LMNA (0.56) | MAPTTP53LMNARXFP1 | |
| SCHEMBL11462119 | 0.88 | MAPT (0.56) | MAPTTP53LMNARXFP1 | |
| SCHEMBL11462895 | 0.86 | MAPT (0.44) | MAPTTP53LMNARXFP1 | |
| SCHEMBL11460555 | 0.85 | MAPT (0.53) | MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2778 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335413-A2 | PROSTHETIC TISSUE VALVES | Cormatrix Cardiovascular, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2023212179-A2 | THERAPEUTIC COMPOSITIONS FOR SKIN DISORDERS AND WOUND REPAIR | UNIVERSITY OF MIAMI (US) | 2023-11-02 | — | — | WO | claimed |
| US-20220110979-A1 | FIBROBLAST REGENERATIVE CELLS | FIGENE, LLC | 2022-04-14 | — | — | US | claimed |
| EP-3908297-A1 | FIBROBLAST REGENERATIVE CELLS | Figene, LLC (US) | 2021-11-17 | — | — | EP | claimed |
| EP-3279663-B1 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-07-28 | — | — | EP | claimed |
| WO-2020146874-A1 | FIBROBLAST REGENERATIVE CELLS | FIGENE, LLC (US) | 2020-07-16 | — | — | WO | claimed |
| EP-3279663-A1 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | The Brigham and Women's Hospital, Inc. (US) | 2018-02-07 | — | — | EP | claimed |
| US-20170281724-A9 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-10-05 | — | — | US | claimed |
| EP-2001496-B1 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-20160228505-A1 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-08-11 | — | — | US | claimed |
| WO-2001015744-A9 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | BRIGHAM & WOMENS HOSPITAL (US) | 2002-09-26 | — | — | WO | claimed |
| EP-1212101-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| JP-2001525058-A | — | — | 2001-12-04 | — | — | JP | claimed |
| WO-2001015744-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-1003501-A4 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM & WOMENS HOSPITAL (US) | 2001-01-17 | — | — | EP | claimed |
| EP-1003501-A1 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1998043630-A1 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1998-10-08 | — | — | WO | claimed |
| US-4442084-A | ABSORPTION, LIQUID PHASE CLAUS PROCESS, RECYCLING | SANDOZ LTD. (CH) | 1984-04-10 | — | — | US | claimed |
| US-4247554-A | ADMINISTERING A QUINAZOLINONE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-01-27 | — | — | US | claimed |
| US-4202895-A | 1-Polyhaloalkyl-2(1H)-quinazolinone derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-05-13 | — | — | US | claimed |